Last reviewed · How we verify
Staphylococcus and Neisseria Tablets
Staphylococcus and Neisseria Tablets is a bacterial vaccine Small molecule drug developed by Peking University Third Hospital. It is currently FDA-approved for Prevention of Staphylococcus infections, Prevention of Neisseria infections. Also known as: H37023540.
This is a vaccine formulation containing antigens from Staphylococcus and Neisseria bacteria designed to stimulate immune responses against these pathogens.
This is a vaccine formulation containing antigens from Staphylococcus and Neisseria bacteria designed to stimulate immune responses against these pathogens. Used for Prevention of Staphylococcus infections, Prevention of Neisseria infections.
At a glance
| Generic name | Staphylococcus and Neisseria Tablets |
|---|---|
| Also known as | H37023540 |
| Sponsor | Peking University Third Hospital |
| Drug class | bacterial vaccine |
| Modality | Small molecule |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The tablet formulation presents bacterial antigens from Staphylococcus and Neisseria species to the immune system, triggering both humoral and cellular immune responses. This approach aims to provide protective immunity against infections caused by these gram-positive and gram-negative bacteria respectively. The exact antigenic composition and delivery mechanism are not publicly detailed.
Approved indications
- Prevention of Staphylococcus infections
- Prevention of Neisseria infections
Common side effects
Key clinical trials
- A Trial on the Treatment of Bronchial Asthma With Budesonide Formoterol Combined With Immune Modulators (Staphylococcus and Neisseria Tablets) (PHASE3)
- Efficacy and Safety of Long-term Oral Staphylococcus Albicans Tablets in Patients With Bronchiectasis (NA)
- Effect of Staphylococcus and Neisseria Tablets on Clinical Outcome Among Patients With Chronic Obstructive Pulmonary Disease (PHASE4)
- Staphylococcus and Neisseria Tablets in the Treatment of Acute Exacerbations of Chronic Obstructive Pulmonary Disease. (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Staphylococcus and Neisseria Tablets CI brief — competitive landscape report
- Staphylococcus and Neisseria Tablets updates RSS · CI watch RSS
- Peking University Third Hospital portfolio CI
Frequently asked questions about Staphylococcus and Neisseria Tablets
What is Staphylococcus and Neisseria Tablets?
How does Staphylococcus and Neisseria Tablets work?
What is Staphylococcus and Neisseria Tablets used for?
Who makes Staphylococcus and Neisseria Tablets?
Is Staphylococcus and Neisseria Tablets also known as anything else?
What drug class is Staphylococcus and Neisseria Tablets in?
What development phase is Staphylococcus and Neisseria Tablets in?
Related
- Drug class: All bacterial vaccine drugs
- Manufacturer: Peking University Third Hospital — full pipeline
- Therapeutic area: All drugs in Immunology / Infectious Disease
- Indication: Drugs for Prevention of Staphylococcus infections
- Indication: Drugs for Prevention of Neisseria infections
- Also known as: H37023540
- Compare: Staphylococcus and Neisseria Tablets vs similar drugs
- Pricing: Staphylococcus and Neisseria Tablets cost, discount & access